A PHASE II TRIAL OF BENDAMUSTINE, CARBOPLATIN AND DEXAMETHASONE (BCD) FOR REFRACTORY OR RELAPSED PERIPHERAL T-CELL LYMPHOMA (BENCART): A CONSORTIUM FOR IMPROVING SURVIVAL OF LYMPHOMA (CISL) TRIAL

Recent advances in understanding and managing T-cell lymphoma

Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL.